| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1476-5829.2010.00248.X |
| P698 | PubMed publication ID | 21848622 |
| P50 | author | Douglas H Thamm | Q61937615 |
| P2093 | author name string | B A Qurollo | |
| B J Rose | |||
| K C Kennedy | |||
| P2860 | cites work | Cancer statistics, 2010 | Q27860525 |
| Cancer statistics, 2009 | Q29547625 | ||
| Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry | Q33527137 | ||
| Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis | Q33751824 | ||
| ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis | Q34706896 | ||
| Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excis | Q34983138 | ||
| Spontaneous and genetically engineered animal models; use in preclinical cancer drug development | Q35761437 | ||
| ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity | Q36146888 | ||
| The epidermal growth factor receptor family | Q36236606 | ||
| Epidermal growth factor receptor (EGFR) signaling in cancer | Q36353031 | ||
| ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. | Q39742390 | ||
| RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target. | Q39769108 | ||
| cDNA microarray profiles of canine mammary tumour cell lines reveal deregulated pathways pertaining to their phenotype | Q39984772 | ||
| A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma. | Q40179159 | ||
| Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis | Q40561379 | ||
| Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. | Q40563034 | ||
| The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients | Q40665439 | ||
| Species identification in cell culture: a two-pronged molecular approach | Q41446660 | ||
| Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. | Q42439751 | ||
| Adjuvant post-operative chemotherapy in bitches with mammary cancer | Q43584037 | ||
| Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors | Q44045921 | ||
| Masitinib is safe and effective for the treatment of canine mast cell tumors | Q46341707 | ||
| A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer | Q46468999 | ||
| Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs | Q46531790 | ||
| Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues | Q46627302 | ||
| Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues. | Q47740831 | ||
| Canine mammary epithelial neoplasms: biologic implications of morphologic characteristics assessed in 232 dogs. | Q53560179 | ||
| P433 | issue | 3 | |
| P921 | main subject | phenotype | Q104053 |
| P304 | page(s) | 196-206 | |
| P577 | publication date | 2010-11-22 | |
| P1433 | published in | Veterinary and Comparative Oncology | Q15759976 |
| P1476 | title | Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell lines | |
| P478 | volume | 9 |
| Q40845711 | A three-dimensional cell culture system as an in vitro canine mammary carcinoma model for the expression of connective tissue modulators |
| Q45887469 | Dual targeting of EGFR and ERBB2 pathways produces a synergistic effect on cancer cell proliferation and migration in vitro |
| Q58765944 | EGF Level in Hepatoid Gland Adenomas and Hepatoid Gland Epitheliomas in Dogs After Administering Tamoxifen |
| Q36034972 | Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells |
| Q38022089 | Prolactin--to be reconsidered in canine mammary tumourigenesis? |
| Q53312576 | Quantification of epidermal growth factor receptor (EGFR) in canine mammary tumours by ELISA assay: clinical and prognostic implications. |
| Q38769796 | The Flint Animal Cancer Center (FACC) Canine Tumour Cell Line Panel: a resource for veterinary drug discovery, comparative oncology and translational medicine. |
Search more.